C-Rad AB (FRA:24C) Total Equity: €32.32 Mil (As of Mar. 2026)


FRA:24C C-Rad AB FRA:24C
90 GF Score
Price €3.14
GF Value €2.85
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is C-Rad AB Total Equity?

C-Rad AB FRA:24C -4.27% 90 Total Equity is €32.32 Mil as of Mar. 2026. GuruFocus rates FRA:24C with a GF Score™ of 90/100 and a GF Value™ of €2.85 (Fairly Valued). The stock has 4 warning signs investors should review.

C-Rad AB's total equity for the quarter that ended in Mar. 2026 was €32.32 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

C-Rad AB Total Equity Historical Data

* Premium members only.

The historical data trend for C-Rad AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

C-Rad AB Total Equity Chart

C-Rad AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.50 22.06 24.24 28.25 31.91

C-Rad AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.05 30.99 32.32 31.91 32.32
FRA:24C
90GF Score
C-Rad AB FRA:24C
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

C-Rad AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

C-Rad AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=46.019-14.11
=31.91

C-Rad AB's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=46.438-14.121
=32.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €32.32 Mil mean?
C-Rad AB (FRA:24C) has a Total Equity of €32.32 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for C-Rad AB and its competitors.
Is C-Rad AB's Total Equity too high?
C-Rad AB's current Total Equity is €32.32 Mil. Overall, C-Rad AB has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's Total Equity compare to ABT and SYK?
C-Rad AB's Total Equity of €32.32 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for C-Rad AB and its competitors. C-Rad AB's current Total Equity is €32.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (FRA:24C) is currently considered Fairly Valued. The stock's GF Value™ is €2.85, compared to a current price of €3.14 — trading 10.2% above its estimated fair value. The current Total Equity is €32.32 Mil. C-Rad AB's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For C-Rad AB (FRA:24C), the current Total Equity is €32.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is C-Rad AB (FRA:24C) Overvalued in 2026?

Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued. The current stock price of €3.14 is trading 10.2% above its estimated GF Value™ of €2.85. GuruFocus considers C-Rad AB to be Fairly Valued.

Key valuation signals for FRA:24C:

  • Total Equity: €32.32 Mil
  • GF Value™: €2.85 vs. price of €3.14 (10.2% above fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the FRA:24C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

C-Rad AB Business Description

Other Exchanges CRAD B:Sweden0R44:UK
Address Sjukhusvagen 12K, Uppsala, SWE, 753 09
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
90GF Score

Get the complete analysis for FRA:24C

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.14
Price
€2.85
GF Value